Serum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, cilt.43, ss.638-644, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 43
- Basım Tarihi: 2021
- Doi Numarası: 10.1111/ijlh.13559
- Dergi Adı: INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.638-644
- Anahtar Kelimeler: biomarker, calprotectin, Hodgkin lymphoma, A9, SUPPRESSOR-CELLS, EXPRESSION, DIFFERENTIATION, CARCINOMA, GROWTH, TARC
- Kocaeli Üniversitesi Adresli: Evet
Özet
Introduction Hodgkin lymphoma (HL) is unusual among malignancies, with inflammation playing such a prominent role in its pathogenesis. S100A8/A9 (calprotectin) is a heterodimeric protein, which has a role in the inflammatory response and oncogenesis. In this study in HL patients, the correlation between serum S100A8/A9 levels and treatment responses was investigated along with whether this marker is correlated with other inflammatory markers.